Osteoporosis is a common bone disease characterized by the progressive loss of bone mass and bone density. Osteoporosis ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has decided it cannot approve Evenity (romosozumab), issuing a negative opinion on the drug for the treatment of severe ...

UCB and Amgen’s osteoporosis drug Evenity has finally been approved in Europe, following a successful appeal against a regulatory rejection, to become the first new drug for the condition since ...

Today, Benzinga's options scanner spotted 11 options trades for Amgen. This isn't normal. The overall sentiment of these ...

Prescription medicine Evenity can make bones stronger but Bristol Medical School says the drug may increase the risk of heart attacks by 30%. UCB, the pharmaceutical firm which produces the drug ...

The success was mainly due to drugs like Tezspire, Blincyto, Evenity, and Tavneos. The company’s sales growth was mainly due ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 42% bearish. Among these notable ...